KIF11 manipulates SREBP2‐dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma
Open Access
- 26 May 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 11 (17) , 3282-3295
Abstract
Cholesterol metabolism is highly correlated with risks of pancreatic ductal adenocarcinoma (PDAC). Nevertheless, the underlying mechanisms of activation of cholesterol biogenesis remain inconclusive. KIF11 is a key component of the bipolar spindle and expresses highly in various malignancies. However, its functional role in PDAC tumorigenesis is still unclear. This study aims to elucidate the oncogenic functions of KIF11 in stimulating cholesterol metabolism, thereby driving PDAC progression. We utilized bioinformatics analysis to identify that KIF11 expressed highly in tumor samples versus paired normal tissues and high KIF11 correlated with high clinical stages of patients. Patients with high KIF11 had worse survival outcomes relative to those with low KIF11. Gene set enrichment analysis (GSEA) revealed that KIF11 correlated intensively with the mevalonate (MVA) metabolic pathway. Positive associations were observed between KIF11 and MVA‐signature (HMGCR, FDFT1, SQLE, and MSMO1). KIF11 could elevate the free cholesterol content of PDAC cells and targeting MVA inhibited the in vitro growth of KIF11‐overexpressing cells. Mechanistically, we found KIF11 could interact with SREBP2, the master regulator of MVA. High KIF11 could increase SREBP2 proteins, but not alter their mRNA levels. KIF11 could attenuate the ubiquitination‐mediated degradation of SREBP2, thereby enhancing its stability and accumulation. Accordingly, KIF11 stimulated the expressions of MVA‐signature and free cholesterol contents depending on SREBP2. In addition, KIF11 depended on SREBP2 to promote cell growth, migration, stemness, and colony formation abilities. The subcutaneous xenograft models indicated that targeting MVA biogenesis (atorvastatin) is effective to restrict the in vivo growth of KIF11high PDAC. Taken together, our study identified that KIF11 could activate the MVA cross talk to drive PDAC progression and inhibiting the KIF11/MVA axis provided a therapeutic vulnerability in the treatment of PDAC.Keywords
This publication has 37 references indexed in Scilit:
- Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment FeaturesGastroenterology, 2018
- JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and ChemoresistanceCell Metabolism, 2018
- The interplay between cell signalling and the mevalonate pathway in cancerNature Reviews Cancer, 2016
- Molecular Pathways: Isocitrate Dehydrogenase Mutations in CancerClinical Cancer Research, 2016
- The Emerging Hallmarks of Cancer MetabolismCell Metabolism, 2016
- The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastomaScience Translational Medicine, 2015
- Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathyBreast Cancer Research and Treatment, 2013
- Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathwayNature, 2013
- Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer AgentsScience, 2013
- LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL ReceptorScience, 2009